C. Gerecke

发表

The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma.

M. Andrulis, R. Bargou, H. Royer, 2005, Blood.

Poly[acrylonitrile‐co‐(N‐vinyl pyrrolidone)] nanoparticles – Composition‐dependent skin penetration enhancement of a dye probe and biocompatibility

A. Lendlein, Wenzhong Li, C. Wischke, 2017, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial

D. Hose, H. Goldschmidt, A. Jauch, 2016, Haematologica.

Stratum corneum targeting by dendritic core-multishell-nanocarriers in a mouse model of psoriasis.

A. Gruber, R. Haag, L. Mundhenk, 2017, Nanomedicine : nanotechnology, biology, and medicine.

The Diagnosis and Treatment of Multiple Myeloma.

H. Einsele, C. Gerecke, S. Knop, 2016, Deutsches Arzteblatt international.

The Efficacy and Toxicity of the RAD Regimen (Revlimid®, Adriamycin®, Dexamethasone) in Relapsed and Refractory Multiple Myeloma - A Phase I/II Trial of “Deutsche Studiengruppe Multiples Myelom”.

H. Einsele, U. Platzbecker, G. Hess, 2007 .

Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis

B. Dörken, H. Einsele, A. Ganser, 2019, Leukemia.

Epigenetic histone modulation contributes to improvements in inflammatory bowel disease via EBI3

C. Gerecke, B. Kleuser, B. Scholtka, 2020, Cellular and Molecular Life Sciences.

Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial

H. Einsele, M. Pfreundschuh, A. Hinke, 2016, Haematologica.

Prospective Randomized Trial of Len/Dex Induction Followed by Tandem MEL140 with Autologous Blood Stem Cell Transplantation and Len Maintenance Versus Continued Therapy with Len/Dex in Myeloma Patients Age 60–75 Years: Protocol-Defined Safety Analysis After 100 Patients

H. Einsele, T. Brümmendorf, F. Bassermann, 2012 .

Formulation and ex vivo evaluation of polymeric nanoparticles for controlled delivery of corticosteroids to the skin and the corneal epithelium

F. F. Sahle, F. Schumacher, R. Bodmeier, 2017, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Tailored dendritic core-multishell nanocarriers for efficient dermal drug delivery: A systematic top-down approach from synthesis to preclinical testing.

Florian Paulus, Emanuel Fleige, Nan Zhang, 2016, Journal of controlled release : official journal of the Controlled Release Society.

Formulation and comparative in vitro evaluation of various dexamethasone-loaded pH-sensitive polymeric nanoparticles intended for dermal applications.

F. F. Sahle, R. Bodmeier, C. Gerecke, 2017, International journal of pharmaceutics.

The glucose transporter GLUT3 controls T helper 17 cell responses through glycolytic-epigenetic reprogramming.

F. Schumacher, E. Abel, B. Ghesquière, 2022, Cell metabolism.

Vitamin C promotes decitabine or azacytidine induced DNA hydroxymethylation and subsequent reactivation of the epigenetically silenced tumour suppressor CDKN1A in colon cancer cells

F. Schumacher, C. Gerecke, L. K. Neubert, 2018, Oncotarget.

Ultrasensitive Detection of Unknown Colon Cancer-Initiating Mutations Using the Example of the Adenomatous Polyposis Coli Gene

U. Gottschalk, C. Gerecke, B. Kleuser, 2013, Cancer Prevention Research.

Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).

H. Einsele, A. Glasmacher, O. Sezer, 2009, Blood.

The Role of Ten-Eleven Translocation Proteins in Inflammation

C. Gerecke, B. Kleuser, T. Homann, 2022, Frontiers in Immunology.

Vitamin C in combination with inhibition of mutant IDH1 synergistically activates TET enzymes and epigenetically modulates gene silencing in colon cancer cells

F. Schumacher, C. Gerecke, B. Kleuser, 2019, Epigenetics.

Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma.

L. Vassilev, L. Cigliano, S. Theurich, 2005, Blood.

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial

D. Hose, H. Goldschmidt, A. Jauch, 2015, Haematologica.

Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2018, Leukemia.

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2015, Leukemia.

GMMG MM5 Trial In Newly Diagnosed Multiple Myeloma To Evaluate PAd Vs VCD Induction Prior To High Dose Treatment Followed By Lenalidomide Consolidation and Maintenance – Final Analysis On Induction Therapy

D. Hose, H. Goldschmidt, A. Jauch, 2013 .

Biocompatibility and characterization of polyglycerol-based thermoresponsive nanogels designed as novel drug-delivery systems and their intracellular localization in keratinocytes

F. Schumacher, M. Calderón, N. Zhang, 2017, Nanotoxicology.

Formulation and in vitro evaluation of polymeric enteric nanoparticles as dermal carriers with pH-dependent targeting potential.

F. F. Sahle, R. Bodmeier, C. Gerecke, 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Response-Adapted Lenalidomide Maintenance in Newly Diagnosed, Transplant-Eligible Multiple Myeloma: Results from the Multicenter Phase III GMMG-MM5 Trial

D. Hose, H. Goldschmidt, A. Jauch, 2017 .

Specific uptake mechanisms of well‐tolerated thermoresponsive polyglycerol‐based nanogels in antigen‐presenting cells of the skin

M. Calderón, Falko Neumann, Nan Ma, 2017, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Comparison of different methods to study effects of silver nanoparticles on the pro- and antioxidant status of human keratinocytes and fibroblasts.

M. Epple, M. Meinke, K. Loza, 2016, Methods.

Lenalidomide (Revlimid™), Adriamycin and Dexamethasone Chemotherapy (RAD) Is Safe and Effective in Treatment of Relapsed Multiple Myeloma - First Results of a German Multicenter Phase I/II Trial.

H. Einsele, G. Hess, R. Bargou, 2006 .

Hypermethylation of ITGA4, TFPI2 and VIMENTIN promoters is increased in inflamed colon tissue: putative risk markers for colitis-associated cancer

U. Gottschalk, C. Gerecke, B. Kleuser, 2015, Journal of Cancer Research and Clinical Oncology.

Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple

H. Einsele, T. Brümmendorf, F. Bassermann, 2022, Blood.